ORACLE INDUSTRY CONNECT, WASHINGTON DC-March 25, 2015-Alliance for Clinical Trials in Oncology Foundation, a nonprofit organization that supports the mission to reduce the impact of cancer, has selected Oracle’s Siebel Clinical Trial Management System and Oracle Health Sciences IRT as the IT platform for a comprehensive, 10-year clinical study, conducted in partnership with a tier-one pharmaceutical company and sponsored by Alliance Foundation Trials (AFT). The solutions will provide a proven platform for the decade-long study as well as future Alliance research initiatives.
“As part of our mission to reduce the impact of cancer, it is imperative that our clinical trials run as successfully and efficiently as possible. Going into a 10-year study, we need a proven, enterprise-scale clinical trial management infrastructure that we can count on today and into the future,” said Monica M. Bertagnolli MD, president, Alliance for Clinical Trials in Oncology Foundation and chief executive officer, AFT. “Oracle Health Sciences applications provided a competitive solution.”
Siebel Clinical Trial Management System will help AFT ensure the efficiency and integrity of its studies, reducing risk while boosting research team productivity. The organization plans to create a centralized trial management database that provides users with the most relevant information based on their specific roles and responsibilities and is designed to speed access to critical data, improve monitoring and patient safety, and keep data secure. Users can also access the system via any browser from any device, further elevating productivity and the user experience.
The deployment of Oracle Health Sciences IRT is designed to enable AFT to more effectively manage patient randomization and global supply chains by extending interactive voice response (IVR) and interactive web response (IWR) systems. AFT also expects to gain the insight needed to change study parameters midstream while reducing service delivery and change-order costs, and looks to optimize the cost of event charges by leveraging the web in addition to the phone for capture.
AFT will benefit from the scalability, cost-effectiveness, and rapid deployment that cloud-based solutions deliver. It plans to leverage Oracle Health Sciences Cloud for Oracle Health Sciences IRT and a third-party cloud service provider for Siebel Clinical Trial Management System.
“Oracle is pleased to support AFT as it embarks on this important 10-year research study. Oracle Health Sciences solutions provide a highly reliable foundation that helps to drive efficient, effective, and insightful research. Our flexible cloud-based delivery options are designed to help AFT achieve faster time to deployment, lower cost of entry, and ready scalability when needed,” said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.